公开(公告)号：WO2007059082A1

公开(公告)日：2007-05-24

申请号：PCT/US2006/044090

申请日：2006-11-13

Applicant: CURAGEN CORPORATION ,  TSE, Kam, Fai ,  POLLACK, Vincent, A. ,  MACDOUGALL, John ,  SHENOY, Suresh, G. ,  MANSFIELD, Traci ,  LICHENSTEIN, Henri ,  JEFFERS, Michael, E. ,  LAROCHELLE, William, J.

Inventor： TSE, Kam, Fai ,  POLLACK, Vincent, A. ,  MACDOUGALL, John ,  SHENOY, Suresh, G. ,  MANSFIELD, Traci ,  LICHENSTEIN, Henri ,  JEFFERS, Michael, E. ,  LAROCHELLE, William, J.

IPC: A61K51/00 ,  G01N33/53 ,  A61K39/395 ,  C12N5/06 ,  C07K16/46

CPC classification number: C07K16/18 ,  A61K47/48469 ,  A61K47/48561 ,  A61K47/48607 ,  A61K47/48638 ,  A61K47/48746 ,  A61K47/6825 ,  A61K47/6849 ,  A61K47/6861 ,  A61K47/6869 ,  A61K47/6897 ,  A61K51/1027 ,  A61K51/106 ,  A61K51/1072 ,  A61K2039/505 ,  B82Y5/00 ,  C07K16/2803 ,  C07K16/2809 ,  C07K16/3038 ,  C07K16/3069 ,  C07K16/42 ,  C07K2317/21 ,  C07K2317/31 ,  C07K2317/34 ,  C07K2317/622 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/92 ,  G01N33/57438 ,  G01N33/57449 ,  G01N2333/705

Abstract: The invention described herein is related to antibodies directed to the antigen TIM-1 and uses of such antibodies for the treatment of cancer (e.g., renal and ovarian cancer). In particular, there are provided fully human monoclonal antibodies directed to the antigen TIM-1. Isolated polynucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions (FR' s) and/or complementarity determining regions (CDR' s), specifically from FRl through FR4 or CDRl through CDR3, are provided. Hybridomas or other cell lines expressing such immunoglobulin molecules and monoclonal antibodies are also provided.

Abstract translation: 本文描述的发明涉及针对抗原TIM-1的抗体和这种抗体用于治疗癌症（例如肾癌和卵巢癌）的用途。 特别地，提供针对抗原TIM-1的完全人单克隆抗体。 编码分离的多核苷酸序列和包含重链和轻链免疫球蛋白分子的氨基酸序列，特别是对应于跨越框架区（FR）和/或互补决定区（CDR）的连续重链和轻链序列的序列，特别是 从FR1到FR4或CDR1到CDR3。 还提供了表达这种免疫球蛋白分子和单克隆抗体的杂交瘤或其它细胞系。

公开(公告)号：WO2012112443A3

公开(公告)日：2012-11-22

申请号：PCT/US2012024860

申请日：2012-02-13

Applicant: IMMUNOMEDICS INC ,  GOLD DAVID V ,  GOLDENBERG DAVID M

Inventor： GOLD DAVID V ,  GOLDENBERG DAVID M

IPC: A61K39/395 ,  G01N33/574

CPC classification number: A61K47/486 ,  A61K47/48569 ,  A61K47/48746 ,  A61K47/6851 ,  A61K47/6859 ,  A61K47/6897 ,  A61K51/0406 ,  A61K51/0491 ,  A61K51/08 ,  A61K51/088 ,  A61K51/1045 ,  A61K51/1057 ,  A61K51/109 ,  A61K51/1096 ,  A61K2039/505 ,  A61K2039/507 ,  B82Y5/00 ,  B82Y15/00 ,  C07K16/303 ,  C07K16/3092 ,  C07K16/44 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/54 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2317/76 ,  G01N33/6854

Abstract: Described herein are compositions and methods of use of anti-pancreatic cancer antibodies or fragments thereof, such as murine, chimeric, humanized or human PAM4 antibodies. The antibodies show novel and useful diagnostic characteristics, such as binding with high specificity to pancreatic and other cancers, but not to normal or benign pancreatic tissues and binding to a high percentage of early stage pancreatic cancers. Preferably, the antibodies bind to pancreatic cancer mucins such as MUC1 or MUC5ac and are of use for the detection and diagnosis of early stage pancreatic cancer. In more preferred embodiments, the anti-pancreatic cancer antibodies can be used for immunoassay of serum samples, wherein the immunoassay detects a marker for early stage pancreatic cancer in serum. Most preferably, the serum is extracted with an organic phase, such as butanol, before immunoassay. Alternatively, immunoassay with PAM4 and anti-CA19.9 antibodies may be utilized to improve sensitivity for pancreatic cancer.

Abstract translation: 本文描述了使用抗胰腺癌抗体或其片段的组合物和方法，例如鼠，嵌合，人源化或人PAM4抗体。 抗体显示出新的和有用的诊断特征，例如对胰腺癌和其他癌症具有高特异性结合，但不对正常或良性胰腺组织结合并结合高百分比的早期胰腺癌。 优选地，抗体结合胰腺癌粘蛋白如MUC1或MUC5ac，并且可用于早期胰腺癌的检测和诊断。 在更优选的实施方案中，抗胰腺癌抗体可用于血清样品的免疫测定，其中免疫测定检测血清中早期胰腺癌的标志物。 最优选地，在免疫测定之前，用有机相如丁醇萃取血清。 或者，可以使用具有PAM4和抗CA19.9抗体的免疫测定来提高胰腺癌的敏感性。

公开(公告)号：WO2012112443A2

公开(公告)日：2012-08-23

申请号：PCT/US2012/024860

申请日：2012-02-13

Applicant: IMMUNOMEDICS, INC. ,  GOLD, David V. ,  GOLDENBERG, David M.

Inventor： GOLD, David V. ,  GOLDENBERG, David M.

IPC: A61K49/00 ,  G01N33/574 ,  A61K49/16 ,  A61K51/10

CPC classification number: A61K47/486 ,  A61K47/48569 ,  A61K47/48746 ,  A61K47/6851 ,  A61K47/6859 ,  A61K47/6897 ,  A61K51/0406 ,  A61K51/0491 ,  A61K51/08 ,  A61K51/088 ,  A61K51/1045 ,  A61K51/1057 ,  A61K51/109 ,  A61K51/1096 ,  A61K2039/505 ,  A61K2039/507 ,  B82Y5/00 ,  B82Y15/00 ,  C07K16/303 ,  C07K16/3092 ,  C07K16/44 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/54 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2317/76 ,  G01N33/6854

Abstract: Described herein are compositions and methods of use of anti-pancreatic cancer antibodies or fragments thereof, such as murine, chimeric, humanized or human PAM4 antibodies. The antibodies show novel and useful diagnostic characteristics, such as binding with high specificity to pancreatic and other cancers, but not to normal or benign pancreatic tissues and binding to a high percentage of early stage pancreatic cancers. Preferably, the antibodies bind to pancreatic cancer mucins such as MUC1 or MUC5ac and are of use for the detection and diagnosis of early stage pancreatic cancer. In more preferred embodiments, the anti-pancreatic cancer antibodies can be used for immunoassay of serum samples, wherein the immunoassay detects a marker for early stage pancreatic cancer in serum. Most preferably, the serum is extracted with an organic phase, such as butanol, before immunoassay. Alternatively, immunoassay with PAM4 and anti-CA19.9 antibodies may be utilized to improve sensitivity for pancreatic cancer.

Abstract translation: 本文描述了抗胰腺癌抗体或其片段如鼠，嵌合，人源化或人PAM4抗体的组合物和使用方法。 这些抗体显示出新的和有用的诊断特征，例如与胰腺癌和其他癌症的高特异性结合，但不与正常或良性胰腺组织结合并与高百分比的早期胰腺癌结合。 优选地，抗体与胰腺癌粘蛋白例如MUC1或MUC5ac结合，并且可用于早期胰腺癌的检测和诊断。 在更优选的实施方案中，抗胰腺癌抗体可用于血清样品的免疫测定，其中免疫测定检测血清中早期胰腺癌的标志物。 最优选地，在免疫测定之前用有机相如丁醇提取血清。 或者，可以利用用PAM4和抗CA19.9抗体的免疫测定来提高对胰腺癌的敏感性。

公开(公告)号：WO2011091113A3

公开(公告)日：2011-09-22

申请号：PCT/US2011021825

申请日：2011-01-20

Applicant: IMMUNOMEDICS INC ,  GOLD DAVID V ,  GOLDENBERG DAVID M

Inventor： GOLD DAVID V ,  GOLDENBERG DAVID M

IPC: G01N33/53 ,  A61K39/00

CPC classification number: A61K47/48746 ,  A61K47/6897 ,  A61K49/0058 ,  A61K51/0406 ,  A61K51/0491 ,  A61K51/08 ,  A61K51/088 ,  A61K51/1018 ,  A61K51/109 ,  A61K2039/505 ,  A61K2039/507 ,  B82Y5/00 ,  B82Y15/00 ,  C07K16/303 ,  C07K16/3092 ,  C07K16/44 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/54 ,  C07K2317/55 ,  C07K2317/565 ,  G01N33/57438 ,  G01N33/57488 ,  G01N2333/4725

Abstract: Described herein are compositions and methods of use of anti-pancreatic cancer antibodies or fragments thereof, such as murine, chimeric, humanized or human PAM4 antibodies. The subject antibodies show a number of novel and useful diagnostic characteristics, such as binding with high specificity to pancreatic and other cancers, but not to normal pancreatic tissues and binding to a high percentage of early stage pancreatic cancers. In preferred embodiments, the antibodies bind to pancreatic cancer mucins. The antibodies and fragments are of use for the detection and diagnosis of early stage pancreatic cancer. In preferred embodiments, the anti-pancreatic cancer antibodies can be used for immunoassay of serum samples, wherein the immunoassay can detect a marker for early stage pancreatic cancer in serum. More preferably, the serum is extracted with an organic phase, such as butanol, before immunoassay.

Abstract translation: 本文描述了使用抗胰腺癌抗体或其片段的组合物和方法，例如鼠，嵌合，人源化或人PAM4抗体。 受试抗体显示出许多新颖且有用的诊断特征，例如对胰腺癌和其他癌症具有高特异性结合，但不与正常胰腺组织结合并结合高百分比的早期胰腺癌。 在优选的实施方案中，抗体结合胰腺癌粘蛋白。 抗体和片段可用于早期胰腺癌的检测和诊断。 在优选的实施方案中，抗胰腺癌抗体可用于血清样品的免疫测定，其中免疫测定可检测血清中早期胰腺癌的标志物。 更优选地，在免疫测定之前，用有机相如丁醇萃取血清。

公开(公告)号：WO2014164913A1

公开(公告)日：2014-10-09

申请号：PCT/US2014/023784

申请日：2014-03-11

Applicant: UNIVERSITY OF UTAH RESEARCH FOUNDATION

Inventor： KOPECEK, Jindrich, Henry ,  YANG, Jiyuan ,  CHU, Te-Wei

IPC: A61K39/00 ,  A61K39/395

CPC classification number: A61K31/712 ,  A61K47/48176 ,  A61K47/48746 ,  A61K47/58 ,  A61K47/6807 ,  A61K47/6849 ,  A61K47/6897 ,  A61K2039/505 ,  C07K16/2887 ,  C07K2317/35 ,  C07K2317/40 ,  C07K2317/55 ,  C07K2317/73

Abstract: In an aspect, the invention relates to compositions, methods, and kits for inducing apoptosis. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

Abstract translation: 一方面，本发明涉及用于诱导凋亡的组合物，方法和试剂盒。 该摘要旨在作为用于在特定技术中进行搜索的扫描工具，而不意在限制本发明。

公开(公告)号：WO2012085789A1

公开(公告)日：2012-06-28

申请号：PCT/IB2011/055730

申请日：2011-12-16

Applicant: KONINKLIJKE PHILIPS ELECTRONICS N.V. ,  ROSSIN, Raffaella ,  LAEPPCHEN, Tilman ,  VAN DEN BOSCH, Sandra Martina ,  ROBILLARD, Marc Stefan ,  VERSTEEGEN, Ronny Mathieu

Inventor： ROSSIN, Raffaella ,  LAEPPCHEN, Tilman ,  VAN DEN BOSCH, Sandra Martina ,  ROBILLARD, Marc Stefan ,  VERSTEEGEN, Ronny Mathieu

IPC: A61K47/48 ,  A61K49/08 ,  A61K51/10 ,  A61K51/04 ,  A61P35/00

CPC classification number: A61K51/044 ,  A61K31/495 ,  A61K45/06 ,  A61K47/4873 ,  A61K47/48746 ,  A61K47/6893 ,  A61K47/6897 ,  A61K51/0495 ,  A61K51/1027 ,  A61K51/1045 ,  A61K51/1093 ,  B82Y5/00

Abstract: Described is a method, and a combination of agents for used therein, by which an agent administered to a subject can be rapidly cleared from circulation. This is achieved by providing an Administration Agent (e.g. a probe for pretargeting) with a reactive group and providing a Clearing Agent with another reactive group, said reactive groups forming a bio-orthogonally reactive pair. Preferably, the reactive pair comprises a cyclooctene or cyclooctyn as one reactant, and a diene as the other reactant. The method and combination can be used for the removal of any bindable molecule from circulation, such as an excess of a pre-targeting probe in the course of a pre-targeting method, a targeting or imaging agent delivered, or the removal of any biomolecule already present in circulation.

Abstract translation: 描述了一种方法，以及其中使用的试剂的组合，通过其可以将施用于受试者的药剂迅速地从循环中清除。 这通过提供与反应性基团的给药剂（例如用于预靶向的探针）并向澄清剂提供另一反应性基团来实现，所述反应性基团形成生物正交反应性对。 优选地，反应性对包括作为一种反应物的环辛烯或环辛烯，和作为其它反应物的二烯。 该方法和组合可用于从循环中除去任何可结合的分子，例如在预靶向法，靶向或成像剂递送过程中过量的预靶向探针，或去除任何生物分子 已经流通。

公开(公告)号：WO2012082841A2

公开(公告)日：2012-06-21

申请号：PCT/US2011/064808

申请日：2011-12-14

Applicant: UNIVERSITY OF MARYLAND, BALTIMORE ,  DAVILA, Eduardo ,  TAMADA, Koji

Inventor： DAVILA, Eduardo ,  TAMADA, Koji

IPC: A61K39/395 ,  A61K31/4188 ,  A61P35/00

CPC classification number: A61K39/39558 ,  A61K35/17 ,  A61K47/4813 ,  A61K47/48584 ,  A61K47/486 ,  A61K47/48615 ,  A61K47/48746 ,  A61K47/555 ,  A61K47/6855 ,  A61K47/6859 ,  A61K47/6863 ,  A61K47/6897 ,  A61K2039/5156 ,  A61K2039/572 ,  A61K2039/585 ,  C07K16/2863 ,  C07K16/44 ,  C07K2317/622 ,  C07K2319/00 ,  C12N5/0636 ,  C12N2501/515 ,  C12N2510/00

Abstract: The present invention provides a universal, yet adaptable, anti-tag chimeric antigen receptor (AT-CAR) system which provides T cells with the ability and specificity to recognize and kill target cells, such as tumor cells, that have been marked by tagged antibodies. As an example, FITC-CAR-expressing T cells have been developed that specifically recognize various human cancer cells when those cells are bound by cancer-reactive FITC-labeled antibodies. The activation of FITC-CAR-expressing T cells is shown to induce efficient target lysis, T cell proliferation, and cytokine/chemokine production. The system can be used to treating subjects having cancer.

Abstract translation: 本发明提供了一种通用但适应性强的抗标签嵌合抗原受体（AT-CAR）系统，其提供T细胞识别和杀死标记有标记抗体的靶细胞如肿瘤细胞的能力和特异性 。 作为示例，已经开发出表达FITC-CAR的T细胞，当这些细胞被癌反应性FITC标记的抗体结合时，T细胞特异性识别各种人类癌细胞。 显示表达FITC-CAR的T细胞的活化诱导有效的靶分解，T细胞增殖和细胞因子/趋化因子产生。 该系统可用于治疗患有癌症的受试者。

公开(公告)号：WO2015134411A1

公开(公告)日：2015-09-11

申请号：PCT/US2015/018365

申请日：2015-03-02

Applicant: ACADEMIA SINICA ,  KAOHSIUNG MEDICAL UNIVERSITY ,  ROFFLER, Steven R.

Inventor： ROFFLER, Steven R. ,  CHENG, Tien-Lu ,  KAO, Chien-Han ,  CHEN, Bing-Mae ,  SU, Yu-Cheng ,  TUNG, Hsin-Yi

IPC: C07K16/46 ,  A61K39/395 ,  A61K47/48 ,  A61K49/00

CPC classification number: A61K47/48746 ,  A61K47/6879 ,  A61K47/6897 ,  A61K49/0002 ,  C07K16/2803 ,  C07K16/2863 ,  C07K16/2887 ,  C07K16/30 ,  C07K16/3061 ,  C07K16/32 ,  C07K16/44 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/35 ,  C07K2317/622 ,  C07K2317/624 ,  C07K2317/73

Abstract: Disclosed herein is a bi-specific antibody that specifically directs a therapeutic agent to a cancer cell by targeting a tumor antigen of the cancer cell, and thereby suppresses the growth of the cancer or blocking the invasion or metastasis of the cancer. The bi-specific antibody of the present disclosure includes a first antigen binding site that binds to polyethylene glycol (PEG); and a second antigen binding site that binds to a target ligand, such as a tumor antigen.

Abstract translation: 本文公开了通过靶向癌细胞的肿瘤抗原来特异性地将治疗剂引导至癌细胞的双特异性抗体，从而抑制癌症的生长或阻断癌症的侵袭或转移。 本公开的双特异性抗体包括结合聚乙二醇（PEG）的第一抗原结合位点; 以及结合靶配体例如肿瘤抗原的第二抗原结合位点。

公开(公告)号：WO2013109939A1

公开(公告)日：2013-07-25

申请号：PCT/US2013/022218

申请日：2013-01-18

Applicant: REGENTS OF THE UNIVERSITY OF MINNESOTA

Inventor： WAGNER, Carston R. ,  LEE, Jae Chul ,  KUMARAPPERUMA, Sidath C.

IPC: C07D475/08 ,  A61K47/48

CPC classification number: A61K47/48561 ,  A61K31/7088 ,  A61K33/24 ,  A61K47/48061 ,  A61K47/48092 ,  A61K47/481 ,  A61K47/48746 ,  A61K47/545 ,  A61K47/549 ,  A61K47/55 ,  A61K47/6849 ,  A61K47/6897 ,  B82Y5/00 ,  C07D475/08 ,  Y10T428/2982

Abstract: The invention provides methods for attaching drugs, dyes or radiolabels to bis-MTX. This method can be used to prepare bis-MTX analogs that can be used to deliver agents, such as nanoparticles, drugs, dyes or radiolabels, to cells.

Abstract translation: 本发明提供了将药物，染料或放射性标记物连接到双-MXX的方法。 该方法可用于制备可用于向细胞递送药剂（例如纳米颗粒，药物，染料或放射性标记物）的双-MTX类似物。

公开(公告)号：WO2012151199A1

公开(公告)日：2012-11-08

申请号：PCT/US2012/035980

申请日：2012-05-01

Applicant: IMMUNOMEDICS, INC. ,  ZENG, Li ,  MITRA, Rohini ,  ROSSI, Edmund A. ,  HANSEN, Hans J. ,  GOLDENBERG, David M.

Inventor： ZENG, Li ,  MITRA, Rohini ,  ROSSI, Edmund A. ,  HANSEN, Hans J. ,  GOLDENBERG, David M.

IPC: A61K51/10

CPC classification number: C07K16/3092 ,  A61K9/0019 ,  A61K9/08 ,  A61K39/3955 ,  A61K39/39591 ,  A61K45/06 ,  A61K47/48369 ,  A61K47/48561 ,  A61K47/48638 ,  A61K47/48676 ,  A61K47/48746 ,  A61K47/6849 ,  A61K47/6869 ,  A61K47/6879 ,  A61K47/6897 ,  A61K51/088 ,  A61K51/1027 ,  A61K51/1045 ,  A61K2039/505 ,  A61K2039/54 ,  A61K2039/545 ,  A61K2039/55505 ,  A61K2039/55511 ,  B82Y5/00 ,  C07K16/065 ,  C07K16/2803 ,  C07K16/2833 ,  C07K16/2851 ,  C07K16/2887 ,  C07K16/2896 ,  C07K16/30 ,  C07K16/3007 ,  C07K16/3069 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/51 ,  C07K2317/515 ,  C07K2317/52 ,  C07K2317/56 ,  C07K2317/94

Abstract: Disclosed are methods, compositions and uses of high concentration antibody or immunoglobulin formulations for subcutaneous, intramuscular, transdermal or other local (regional) administration, in a volume of than 3, less than 2 or less than 1 ml. Preferably, the formulation contains a high concentration formulation (HCF) buffer comprising phosphate, citrate, polysorbate 80 and mannitol at a pH of about 5.2. The formulation more preferably comprises at least 100, 150, 200, 250 mg/ml or 300 mg/ml of antibody. The methods for preparing the high concentration formulation include ultrafiltration and diafiltration to concentrate the antibody and exchange the medium for HCF buffer. Other embodiments concern use of non-G1m1 (nG1m1) allotype antibodies, such as G1m3 and/or a nG1m1,2 antibodies. The nG1m1 antibodies show decreased immunogenicity compared to G1m1 antibodies.

Abstract translation: 公开了体积超过3，小于2或小于1ml的高浓度抗体或免疫球蛋白制剂用于皮下，肌内，透皮或其它局部（区域）给药的方法，组合物和用途。 优选地，制剂含有在约5.2的pH下含有磷酸盐，柠檬酸盐，聚山梨醇酯80和甘露糖醇的高浓度制剂（HCF）缓冲液。 制剂更优选包含至少100,150,200,250mg / ml或300mg / ml的抗体。 制备高浓度制剂的方法包括超滤和渗滤以浓缩抗体并将介质交换用于HCF缓冲液。 其他实施方案涉及非G1m1（nG1m1）同种异型抗体如G1m3和/或nG1m1,2抗体的使用。 与G1m1抗体相比，nG1m1抗体的免疫原性降低。